Psilocybin reduces binge eating episodes by 80%
Tryp Therapeutics recently announced interim results from its Phase II trial with psilocybin in the treatment of binge eating disorder, with daily binge eating episodes reduced by an average of 80%.
To discuss the study and the company’s drug development programmes, PSYCH spoke with Tryp’s CEO and Chief Scientific Officer Jim Gilligan.
‘We teed up several clinical studies with oral psilocybin while we’re developing TRP-8803, our proprietary product which is an IV infusion of psilocin,’ explained Gilligan.
‘These studies are in eating disorders and nociplastic pain, to confirm that we will see a clinical benefit that we can accelerate.’READ MORE